Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
Sponsor: argenx
Summary
This study aims to assess the safety of ARGX-124 in healthy adults. Another aim is to measure the amount of ARGX-124 in the blood over time to learn how it acts and moves in the body and how the immune system responds to it. Participants will remain in the study for up to approximately 23 weeks.
Official title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-124 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2026-01-26
Completion Date
2026-12-31
Last Updated
2026-03-06
Healthy Volunteers
Yes
Conditions
Interventions
ARGX-124
Administrations of ARGX-124
Placebo
Administrations of placebo comparator
Locations (1)
Altasciences
Montreal, Canada